Nishimura Seiichiro, Takahashi Kaoru, Akiyama Futoshi, Oguchi Masahiko, Tada Keiichiro, Makita Masujiro, Iwase Takuji, Yoshimoto Masataka, Yamashita Takashi, Sakamoto Goi, Kasumi Fujio
Department of Breast Surgery, Cancer Institute Ariake Hospital, 3-10-6, Ariake, Koto-ku, Tokyo 135-8550, Japan.
Breast Cancer. 2005;12(2):112-7. doi: 10.2325/jbcs.12.112.
To classify and assess ipsilateral breast tumor recurrences (IBTR) after breast-conserving therapy.
Between 1986 and 2001, 2,137 patients who had breast cancer underwent breast-conserving surgery with or without radiotherapy at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Of these patients, 83 (3.9%) had an IBTR. We classified the IBTR as a new primary cancer (NP) if the primary tumor had completely negative margins at first operation by detailed pathological examination and if the IBTR had an intraductal component. All other IBTRs were judged true local recurrence (TR).
Of the 83 patients, 42 patients were classified as TR (29 had no radiotherapy) and 41 as NP (40 had no radiotherapy). Mean time to disease recurrence was 37 months for TR (52% were within 2 years) versus 55 months for NP (19% were within 2 years) (p=0.031). Six patients (14%) with TR did not receive re-operation, and 67% received salvage mastectomy and 19% re-lumpectomy. All cases of NP were operable, 78% underwent salvage mastectomy and 22% underwent re-lumpectomy. Distant metastases were observed in 33% of patients with TR and 5% of patients with NP, and cause-specific death occurred in 6 cases with TR and in one with NP. The patients with NP had improved 5-year rates of overall survival (NP 91% vs. TR 76%, P=0.0627) and distant disease-free survival (NP 93% vs. TR 61%, P=0.0028). Patients with NP more often developed contralateral breast cancer (NP 37% vs. TR 12%, P=0.018)
Patients with NP had better survival rates than those with TR. Distinguishing new primary breast carcinomas from local disease recurrences may have importance in therapeutic decisions and chemoprevention strategies.
对保乳治疗后同侧乳腺肿瘤复发(IBTR)进行分类和评估。
1986年至2001年间,2137例乳腺癌患者在日本癌症研究基金会癌症研究所医院接受了保乳手术,部分患者还接受了放疗。其中,83例(3.9%)出现IBTR。如果通过详细病理检查发现原发肿瘤在首次手术时切缘完全阴性,且IBTR具有导管内成分,我们将该IBTR分类为新发原发性癌症(NP)。所有其他IBTR均判定为真性局部复发(TR)。
83例患者中,42例被分类为TR(29例未接受放疗),41例为NP(40例未接受放疗)。TR组疾病复发的平均时间为37个月(52%在2年内),而NP组为55个月(19%在2年内)(p = 0.031)。6例(14%)TR患者未接受再次手术,67%接受了挽救性乳房切除术,19%接受了再次肿块切除术。所有NP病例均可手术,78%接受了挽救性乳房切除术,22%接受了再次肿块切除术。TR组33%的患者和NP组5%的患者出现远处转移,TR组6例患者和NP组1例患者发生特定原因死亡。NP组患者的5年总生存率(NP为91%,TR为76%,P = 0.0627)和远处无病生存率(NP为93%,TR为61%,P = 0.0028)有所提高。NP组患者更常发生对侧乳腺癌(NP为37%,TR为12%,P = 0.018)。
NP患者的生存率高于TR患者。区分新发原发性乳腺癌与局部疾病复发可能对治疗决策和化学预防策略具有重要意义。